Why One-Size-Fits-All Inhalers Fail: The Rise of Precision Medicine for Asthma
Source PublicationMolecular Biology Reports
Primary AuthorsSanap, Gupta, Kabra et al.
Did you know your asthma isn't the same as your friend's?
For decades, we treated asthma like a single condition. If you wheezed, you got the same standard inhaler. But science shows asthma has many different biological profiles, which is why basic treatments fail for moderate-to-severe cases.
The Shift to Precision Medicine for Asthma
A new review highlights how doctors are moving away from one-size-fits-all treatments. Instead, they use precision medicine for asthma to target the specific biological pathways causing the inflammation. This matches the therapy to your body's unique immune response.
How Biomarkers Guide the Treatment
Researchers analysed how biological markers—like specific white blood cells (eosinophils) and exhaled gas levels—help identify a patient's exact asthma profile. Doctors can then select targeted biologic therapies:
- Anti-IgE therapies to block allergic triggers.
- Anti-IL-5 or anti-IL-4/13 agents to stop specific inflammatory proteins.
- Anti-TSLP agents that target the start of the lung's alarm system.
Data shows these targeted therapies significantly reduce severe attacks and lower the need for steroid pills.
The Future and the Hurdles
This approach suggests a future with fewer hospital visits and better symptom control. However, high costs, safety monitoring, and treatment adherence remain major challenges. Researchers are now testing new delivery systems to make these therapies more accessible.